Government, non NIH

MATRIX Technology Accelerator Domain 1 Prevention Challenges: Overcoming Impediments to HIV Prevention

Grant Source: 

This project is made possible by the generous support of the American people through the United States Agency for International Development (USAID) through the United States President’s Emergency Plan for AIDS Relief (PEPFAR), under the terms of Cooperative Agreement #AID-OAAA-17-00015. The contents are the responsibility of PATH and do not necessarily reflect the views of MATRIX, USAID, PEPFAR, or the United States government.

MATRIX Prevention Challenges RFA

Grant Source: 

The MATRIX Prevention Challenges RFA is now open. The objective of this funding opportunity is to support the development of solutions to specific challenges facing the field of HIV prevention. Investigators and institutions from Kenya, South Africa, Zimbabwe, United States (US), European Union (EU), or United Kingdom (UK), are invited to apply to this request for applications (RFA) sponsored by MATRIX: A USAID Project to Advance the Research and Development of Innovative HIV Prevention Products for Women. 

Increasing Uptake of Long-Acting Injectable Antiretrovirals Among People with HIV

Grant Source: 

This notice announces the opportunity to apply for funding under the Increasing Uptake of Long-Acting Injectable Antiretrovirals Among People with HIV cooperative agreement Increasing viral suppression and client retention in care are critical components of meeting the goals of the National HIV/AIDS Strategy (2022-2025) and ending the HIV epidemic. In order to reach these goals, it is imperative for HIV care communities to address health care inequities. With the advent of FDA-approved long-acting injectable (LAI) antiretroviral (ARV) medication formulations, initiatives that promote, facilitate, and evaluate the uptake and ongoing utilization of LAI ARV medication may improve clinical outcomes for people with HIV, especially for minority populations who continue to face disparate health care inequities and stigma. This project is designed to develop protocols, implement them and modify as needed, to increase uptake of LAI ARV medications among people of color with HIV, since LAI ARV medications may offer benefits in addressing health inequities and achieving viral suppression.

Health Topics: 

Accelerating impact of long-acting technologies in low- and middle-income countries (LMICs)

Grant Source: 

Safe and efficacious medicines are available for the prevention and treatment of major diseases, but their effectiveness can be compromised by poor treatment completion. Lack of adherence can worsen clinical outcomes, leading to increased mortality, persistent transmission and increased drug resistance in the case of antimicrobials and antivirals. Analyses of treatment and prevention of HIV, malaria, and TB within public health programs show wide disparities in rates of completion, especially among specific populations and regions.

Application Deadline: 23 April 2019